For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website is to provide initial guidance only and it does ...

In adults with postherpetic neuralgia, neurontin therapy may be initiated as a single 300-mg dose on day 1, 600 mg/day on day 2 in divided doses and 900 mg/day on day 3 in divided doses. Patients > 12 ...

MIAMI--(BUSINESS WIRE)--May 2, 2005--IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that it received final approval on April 29, 2005 from the U.S. Food and Drug Administration (FDA ...

In January 2025, we reported that some adverse events associated with gabapentin (Neurontin) may have been overestimated. Since then, new risks related to gabapentin emerged and prescribing continued ...

The gabapentin market is capturing a valuation of US$ 2.11 billion in 2023 and is predicted to reach US$ 3.54 billion by 2033. The market is registering a CAGR of 5.3% during the forecast period. How ...

It’s fast becoming the go-to drug for addicts in search of a stronger high — and it is not even an opioid. Gabapentin, a purportedly nonaddictive painkiller primarily used to treat shingles and ...

Gabapentin is a prescription anticonvulsant used for seizures and nerve pain, sold under names like Neurontin and Gralise, ...

Gabapentin tablets are indicated for management of postherpetic neuralgia in adults; and as an adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalisation, ...

Zydus Lifesciences Limited reported that it secured final approval from the United States Food and Drug Administration (USFDA) for manufacturing and marketing Gabapentin Tablets (Once-Daily), ...

Ahmedabad: Zydus Lifesciences Limited, received tentative approval from the United States Food and Drug Administration (USFDA) for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg (USRLD: Gralise ...